UNSPSC 51263159: Celiprolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C20H33N3O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G1M3398594, chemically known as 3-(3-acetyl-4-(3-((tert-butyl)amino)-2-hydroxypropoxy)phenyl)-1,1-diethyluronium chloride but more generally known as celiprolol hydrochloride, which bears US NIH Compound Identifier 42373. European Medicines Agency schedules Celiprolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01146MIG.

UNSPSC 51263159 Celiprolol hydrochloride is a Commodity code that shows minimal recent activity aligned with its nominal pharmaceutical scope. The single recent state-local opportunity on file—Seminole County, Florida's IFB60459723LAS—is not a purchase of celiprolol hydrochloride but rather naloxone and drug deactivation systems, indicating a misalignment between the code assignment and the actual work being procured. State and local governments do solicit pharmaceutical products and medical supplies through UNSPSC taxonomy, but this particular code does not reflect active demand for celiprolol or related cardiovascular agents in the current state-local procurement market based on available recent records.

Seminole County, Florida posted the sole recent opportunity under this code on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through a competitive IFB process with quarterly deliveries to the Seminole County Community Health Building. The mismatch between the code's pharmaceutical designation and the naloxone/drug-deactivation scope suggests either a data-entry error or a broad-brush code assignment that does not reflect current buying patterns. No additional recent state-local opportunities appear in the record for celiprolol hydrochloride itself, limiting visibility into genuine demand and issuing-body concentration for this specific therapeutic agent.